Mr. Shorrock was appointed President and Chief Executive Officer in September 2025 following the announcement of the Company’s pivot to a digital asset treasury strategy centered on BNB, a native cryptocurrency of the Binance blockchain ecosystem. He previously served as Chief Legal Officer and Executive Director of Business Development (April 2021-September 2025) and as President of LineaRx, the Company’s biotherapeutics subsidiary (December 2024-September 2025). During his tenure, Mr. Shorrock has led the Company’s legal, regulatory, risk mitigation, intellectual property and business development functions and has been instrumental in the development of the Company’s LineaDNA and LineaIVT platforms. Mr. Shorrock previously served as general and intellectual property counsel to the Company (November 2016-April 2019).
Prior to rejoining the Company in 2021, Mr. Shorrock practiced in the intellectual property groups at Lowndes, Drosdick, Doster, Kantor & Reed, P.A. (2020-2021) and Allen, Dyer, Doppelt & Gilchrist, P.A. (2019-2020). Earlier in his career, he was an associate at New Jersey law firms focused on intellectual property and complex commercial transactions.
Mr. Shorrock holds a B.A. in Biology from Franklin and Marshall College and a J.D., with a concentration in intellectual property, from Seton Hall University Law School.
Prior to being appointed as Chief Financial Officer of Applied DNA Sciences, Ms. Jantzen was the Controller for the Company since May of 2013. Ms. Jantzen is a certified public accountant with over 15 years financial and accounting experience.
Prior to joining the Company Ms. Jantzen was a senior manager at Marcum LLP, since June 9, 2014, where she managed multiple engagements and specialized in SEC policies, practices and procedures, including Sarbanes-Oxley compliance as well as valuations involving acquisitions. Ms Jantzen was named Who’s Who in Accounting/Audits by Long Island Business News in 2012.
Mr. Horsman was appointed Chief Investment Officer of BNB Plus in October 2025. He leads the company’s BNB digital asset treasury strategy and represents the company globally at conferences and with investors and media.
• Co-Founder of Coral Capital, a DeFi hedge fund (2021); GP acquired by DNA Fund in 2024
• Founder of Verified Organic, an Ethereum blockchain platform focused on track-and-trace technology for organic farming built in partnership with Consensys (2018)
• Co-Founder of Innovation Shares; including NYSE: KOIN Blockchain ETF, and NYSE: THCX Cannabis ETF (2017)
• CIO of Esoteric Strategies, a hedge fund focused on arbitrage of the Grayscale public trusts GBTC and ETHE (2016)
• Co-Founder and Managing Partner of Integrated Ag, $270M Ag-focused PE RE Fund (2012)
• Co-Founder and COO of Merion Investment Management, $1.2B litigation finance hedge fund (2009)
• Co-Founder and Managing Partner of Blue Sand Securities, a placement agent that raised $15B for single-manager hedge funds (2002)
• Chartered Financial Analyst (CFA) (2006)
• BS in Accounting, Finance, and Entrepreneurship, University of Arizona Eller School of Business (2002)